ALLY three-lens brief
Evidence-based stock research on ALLY. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- P/E of 8.8 — trading at a value multiple.
- Analyst mean target $47.34 — 24% above current (18 analysts).
ALLY closed at $38.27 (+1.59%) as of 2026-11-12. Market cap: $11.48B. P/E (trailing) 8.8. Price is below the 50-day MA and below the 200-day MA. Positives: p/E of 8.8 — trading at a value multiple.; analyst mean target $47.34 — 24% above current (18 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $2.33B, net income $401.00M.
Why three lenses on ALLY, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ALLY across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/ALLY" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ALLY brief"></iframe>